Program

ISCT is pleased to present an interactive Preliminary Program to help you plan your ISCT 2017 London experience.

What’s new for 2017?

  • 6 Hot Topic Roundtable sessions designed to cover the most cutting edge issues in the field
  • Oral Abstract Presentations will be in Plenary Breakout Sessions alongside world renowned plenary speakers
  • Corporate Product Theatres – a chance to view new technologies, cutting edge product presentations, and corporate profiles

Click each session for confirmed speakers – updated March 7, 2017

Pre-Conference Day

Session Type
Cell Processing Track
Global Regulatory Perspectives (GRP)
Cord Blood Series
Cord Blood Quality Bootcamp
State of the Art in European MSC Clinical Trials
Corporate
07:00
07:30
08:00
08:30
09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
17:30
18:00
18:30
19:00
19:30
20:00
20:30
21:00
21:30
Cell Processing Track Session 1 - ISCT-EBMT Joint Session: The Evolving Role of the Stem Cell Lab Part 1
Click to view confirmed speakers
Cell Processing Track Session 1 - ISCT-EBMT Joint Session: The Evolving Role of the Stem Cell Lab Part 1
08:00 - 10:30
Click to view confirmed speakers
Chair:
Mark Lowdell, PhD, FRCPath, FRSB, Royal Free Hopsital and University College London, United Kingdom
Speakers:
Boris Calmels, PharmD, PhD, Institut Paoli-Calmettes, France
Automation of HSCT processing

Christian Chabannon, MD, PhD, Institut Paoli Calmettes, France
High dose therapy and autologous HSCT for CaBr – time to revisit?

Ineke Slaper-Cortenbach, PhD, ZonMw, Netherlands
Challenges of accommodating GMP in hospital based labs supporting ATMP Trials

Paolo Muraro, MD, PhD, Imperial College London, United Kingdom
Current State of the Art in HSCT for MS

Welcome and Regulatory Roundup
Click to view confirmed speakers
Welcome and Regulatory Roundup
Speakers:
Karen Nichols, Esq.,VP, Regulatory and Quality, NantKwest Inc., United States
Dominic Wall, PhD, FFSc(RCPA), Operations Director, Peter MacCallum Cancer Centre, Australia
Scott Burger, MD, Principal, Advanced Cell & Gene Therapy, United States

Global Regulatory Perspectives Workshop Session 1 - Genetic Modification
Click to view confirmed speakers
Global Regulatory Perspectives Workshop Session 1 - Genetic Modification
08:30 - 10:00
Click to view confirmed speakers
Moderator:
David DiGiusto, PhD, Executive Director, Stem Cells and Cellular Therapeutics Operations, Stanford Healthcare, United States
Speakers:
Matthias Renner, PhD, Deputy Head Non-Viral Gene Transfer Medicinal Products, Paul-Ehrlich-Institut, Germany
Michael Havert, PhD, Gene Therapy Reviewer, FDA, United States
Anne Dupraz Poiseau, PhD, Chief Regulatory Officer, Orchard Therapeutics, Ltd, United Kingdom

Case Study I
Case Study I

Cell Processing Track Session 2 - The Evolving Role of the Stem Cell Lab Part 2
Click to view confirmed speakers
Cell Processing Track Session 2 - The Evolving Role of the Stem Cell Lab Part 2
10:45 - 12:45
Click to view confirmed speakers
Chair:
Jaap Jan Boelens, MD, PhD, UMC Utrecht, Netherlands
Christian Chabannon, MD, PhD, Institut Paoli Calmettes, France
Speakers:
Ronjon Chakraverty, MBChB, PhD, University College London, United Kingdom
Novel strategies for Alloreactive ex-vivo T cell depletion

Martin Hildebrandt, MD, Technische Universität München, Germany
From Tissues and Cells to ATMPs – Definitions and Challenges

Mikkel Rosendahl, PhD, Copenhagen University Hospital, Denmark
Ovarian tissue cryopreservation for reconstitution of fertility post radiotherapy

Mark Lowdell, PhD, FRCPath, FRSB, Royal Free Hospital and University College London, United Kingdom
The role of the hospital Stem Cell Lab in delivery of ATMPs for clinical trials

Global Regulatory Perspectives Workshop Session 2 - Global Strategy for Development and Supply of Gene-Modified Cell Products
Click to view confirmed speakers
Global Regulatory Perspectives Workshop Session 2 - Global Strategy for Development and Supply of Gene-Modified Cell Products
10:45 - 12:15
Click to view confirmed speakers
Moderator:
Christopher Bravery, PhD, Consulting Regulatory Scientist, Consulting on Advanced Biologicals Ltd., United Kingdom
Speakers:
Martha French, BS, Vice President of Regulatory Affairs, Bellicum Pharmaceuticals, Inc.,United States

Case Study II
Case Study II

Lunch with Exhibits
Lunch with Exhibits
12:45 - 13:45

Cell Processing Track Session 3 - Product Characterization by Flow Cytometry Part 1
Click to view confirmed speakers
Cell Processing Track Session 3 - Product Characterization by Flow Cytometry Part 1
13:45 - 14:45
Click to view confirmed speakers
Speakers:
Ruud Hulpas, PhD, Cellular Technologies Bioconsulting, United States
Challenges in Flow Cytometry for Commercial Cell Therapy

John T. Elliott, PhD, NIST, United States
Using Artificial Reference Materials on a Flow Cytometer

Luisa de Jesus Saraiva, PhD, National Institute for Biological Standards and Control, United Kingdom
Biological Reference Material for Flow Cytometry

Global Regulatory Perspectives Workshop Session 3- Replication Competent Vector Testing of Gene-Modified Cell Therapy Products
Click to view confirmed speakers
Global Regulatory Perspectives Workshop Session 3- Replication Competent Vector Testing of Gene-Modified Cell Therapy Products
13:45 - 14:45
Click to view confirmed speakers
Moderator:
Janet MacPherson, PhD, Development Manager, Royal Prince Alfred Hospital, Australia
Speakers:
Michael Havert, PhD, Gene Therapy Reviewer, FDA, United States
James Miskin, PhD, Chief Technical Officer, Oxford BioMedica, United Kingdom

Cell Processing Track Session 4 - Product Characterization by Flow Cytometry Part 2
Click to view confirmed speakers
Cell Processing Track Session 4 - Product Characterization by Flow Cytometry Part 2
15:00 - 16:15
Click to view confirmed speakers
Speakers:
Harry Dolstra, PhD, ‎Radboud University Nijmegen Medical Centre, Netherlands
Flow Cytometry-based QC Analysis of Cell Therapy Products

Renold Capocasale, BSc, FlowMetric Inc, United States
Validated Flow Cytometry: A Critical Check Point for Cellular Therapeutics

Tamara Laskowski, PhD, MD Anderson Cancer Center, United States
Harnessing the power of high-throughput multi-parameter flow cytometry to improve analysis of CAR T-cell cytotoxic function

Global Regulatory Perspectives Workshop Session 4 - Clinical Trials - Patient Populations in Developing Regulatory Regions
Click to view confirmed speakers
Global Regulatory Perspectives Workshop Session 4 - Clinical Trials - Patient Populations in Developing Regulatory Regions
15:00 - 16:30
Click to view confirmed speakers
Moderator:
Dominic Wall, PhD, FFSc(RCPA), Operations Director, Peter MacCallum Cancer Centre, Australia
Speakers:
Azizah Ab Ghani, PhD, Senior Principal Assistant Director, Head of Biologics Section, National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia, Malaysia
Peter Olagunju, MBA, ASQ-CQA, Senior Director, Commercial CMC Operations, bluebird bio, United States

Case Study III & Closing Remarks
Case Study III & Closing Remarks
16:30 - 17:15

ISCT 2017 President's Welcome
ISCT 2017 President's Welcome

Exhibit Open House and 25th Anniversary Silver Jubilee Celebration
Exhibit Open House and 25th Anniversary Silver Jubilee Celebration
19:30 - 21:30

ISCT-CBA Cord Blood Series Session 1 - CBT as a Platform for Cellular Therapy
Click to view confirmed speakers.
ISCT-CBA Cord Blood Series Session 1 - CBT as a Platform for Cellular Therapy
08:00 - 10:30
Click to view confirmed speakers.
Chair:
Juliet Barker, MBBS, Memorial Sloan Kettering Cancer Center, United States
Speakers:
Juliet Barker, MBBS, Memorial Sloan Kettering Cancer Center, United States
Elizabeth J. Shpall, MD, MD Anderson Cancer Center, United States
Jaap Jan Boelens, MD, PhD, UMC Utrecht, Netherlands

ISCT-FACT Cord Blood Quality Boot Camp Session 1
ISCT-FACT Cord Blood Quality Boot Camp Session 1
08:00 - 10:30

State of the Art in European MSC Clinical Trials Session 1
Organized by the ISCT MSC Committee in cooperation with the European Commission
State of the Art in European MSC Clinical Trials Session 1
08:00 - 10:30
Organized by the ISCT MSC Committee in cooperation with the European Commission
Chair:
Jacques Galipeau, MD FRCP(C), University of Wisconsin in Madison, United States
Speakers:
Frank Barry, PhD, REMEDI Regenerative Medicine Institute, Ireland
Eleuterio Lombardo,PhD, TiGenix SAU, Spain
Antonio Uccelli, MD, University of Genoa Department of Neurosciences, Italy
Charles Kessler, PhD, European Commission, Belgium
Willem Fibbe, MD, PhD, Leiden University Medical Center, Netherlands

- Introduction
- The EU Perspective on advanced MSC clinical trials
- MSC biology and manufacturing challenges
- MSC for GvHD
- MSC for multiple sclerosis

ISCT-CBA Cord Blood Series Session 2 - Immunotherapy
Click to view confirmed speakers
ISCT-CBA Cord Blood Series Session 2 - Immunotherapy
10:45 - 12:45
Click to view confirmed speakers
Chair:
Elizabeth J. Shpall, MD, MD Anderson Cancer Center, United States
Speakers:
Colleen Delaney, MD, MSc, Nohla Therapeutics, United States
Catherine Bollard, MBChB, MD, Children's National Medical Center and The George Washington University, United States
Katy Rezvani, MD, PhD, MD Anderson Cancer Center, United States

ISCT-FACT Cord Blood Quality Boot Camp Session 2
ISCT-FACT Cord Blood Quality Boot Camp Session 2
10:45 - 12:45

State of the Art in European MSC Clinical Trials Session 2
Organized by the ISCT MSC Committee in cooperation with the European Commission
State of the Art in European MSC Clinical Trials Session 2
10:45 - 12:45
Organized by the ISCT MSC Committee in cooperation with the European Commission
Chair:
Ivan Martin, PhD,University Hospital Basel, Switzerland
Speakers:
Enrique Gomez Barrena, MD, PhD, Hospital Universitario La Paz, Spain
Jens Kastrup, MD, DMSC, Rigshospitalet, Denmark
Christian Jorgensen, MD, PhD,Institute for Regenerative Medicine & Biotherapy (IRMB), France

- MSC for Osteoarthritis
- MSC for bone repair
- MSC for cartilage repair
- MSC for cardiac repair

Corporate Product Theatre - Available
Contact Brian Poole (brian@celltherapysociety.org) for more information.
Corporate Product Theatre - Available

Corporate Product Theatre - Available
Contact Brian Poole (brian@celltherapysociety.org) for more information.
Corporate Product Theatre - Available

ISCT-CBA Cord Blood Series Session 3 - Regenerative Medicine for Pediatric Diseases
Click to view confirmed speakers
ISCT-CBA Cord Blood Series Session 3 - Regenerative Medicine for Pediatric Diseases
13:45 - 14:45
Click to view confirmed speakers
Chair:
Joanne Kurtzberg, MD, Duke University Medical Center, United States
Speakers:
Joanne Kurtzberg, MD, Duke University Medical Center, United States

ISCT-FACT Cord Blood Quality Boot Camp Session 3
ISCT-FACT Cord Blood Quality Boot Camp Session 3
13:45 - 14:45

State of the Art in European Clinical Trials Session 3
Organized by the ISCT MSC Committee in cooperation with the European Commission
State of the Art in European Clinical Trials Session 3
13:45 - 14:45
Organized by the ISCT MSC Committee in cooperation with the European Commission
Chair:
Katarina LeBlanc, MD, PhD, Karolinska University Hospital Huddinge, Sweden
Speakers:
Francesco Dazzi, MD, PhD King's College London, United Kingdom

- MSC for sepsis - MSC for kidney transplantation

ISCT-CBA Cord Blood Series Session 4 - Autologous Regulation
ISCT-CBA Cord Blood Series Session 4 - Autologous Regulation
15:00 - 16:15
Speakers:
Jonathan Kimmelman, PhD, McGill University, Canada

ISCT-FACT Cord Blood Quality Boot Camp Session 4
ISCT-FACT Cord Blood Quality Boot Camp Session 4
15:00 - 16:15

Corporate Symposium - Miltenyi Biotec
Corporate Symposium - Miltenyi Biotec
16:30 - 18:30

Pre-Conference Day
Session Type
Hot Topics
Plenary Sessions
Plenary Breakout Sessions
Regulatory Track
Strategies for Commercialization Track
Quality and Operations Track
Corporate
07:00
07:30
08:00
08:30
09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
17:30
18:00
18:30
19:00
19:30
Outer Column
Outer Column
Hot Topic Roundtable Session 1 - Potency Assays in ATMP Development and Delivery
Hot Topic Roundtable Session 1 - Potency Assays in ATMP Development and Delivery
07:30 - 08:30

Hot Topic Roundtable Session 2 - Advances in Stem Cell Based Therapeutics for Cancer
Click to view confirmed speakers
Hot Topic Roundtable Session 2 - Advances in Stem Cell Based Therapeutics for Cancer
07:30 - 08:30
Click to view confirmed speakers
Chair:
Massimo Dominici, MD University of Modena and Reggio Emilia, Italy
Khalid Shah, MS, PhD, MGH, Harvard Medical School, United States
Speakers:
Massimo Dominici, MD University of Modena and Reggio Emilia, Italy
Khalid Shah, MS, PhD, MGH, Harvard Medical School, United States
Samuel Janes, MBBS, PhD, University College London, United Kingdom

Plenary Session 1 - Presidential Plenary on T-Cell Immunotherapy
Click to view confirmed speakers
Plenary Session 1 - Presidential Plenary on T-Cell Immunotherapy
09:00 - 10:30
Click to view confirmed speakers
Chair:
Catherine Bollard, MBChB, MD, Children's National Medical Center and The George Washington University, United States
Speakers:
Martin Pule, MB BCh, University College London, United Kingdom
Helen Heslop, MD, DSc (Hon), Baylor College of Medicine, United States
Chiara Bonini, MD, San Raffaele Scientific Institute, Italy

Coffee Break with Exhibits
Coffee Break with Exhibits

T-Cell Immunotherapy Plenary Breakout Session 1 - Virus Specific T Cells
Click to view confirmed speakers
T-Cell Immunotherapy Plenary Breakout Session 1 - Virus Specific T Cells
11:00 - 12:15
Click to view confirmed speakers
Chair:
Helen Heslop, MD, DSc (Hon), Baylor College of Medicine, United States
Speakers:
Karl Peggs, MD, MRCP, FRCPath, University College London, United Kingdom
Ann Leen, PhD, Baylor College of Medicine, United States

Oral Abstract Presentations:

Allistair Abraham

Children's National Medical Center, United States
SUCCESSFUL ENGRAFTMENT BUT HIGH VIRAL REACTIVATION AFTER REDUCED INTENSITY UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION FOR SICKLE CELL DISEASE

Michael Keller
Children's National Medical Center, United States
ADOPTIVE T CELL IMMUNOTHERAPY RESTORES TARGETED ANTIVIRAL IMMUNITY IN IMMUNODEFICIENT PATIENTS

T-Cell Immunotherapy Plenary Breakout Session 2 - Gene Engineered T Cells
Click to view confirmed speakers
T-Cell Immunotherapy Plenary Breakout Session 2 - Gene Engineered T Cells
11:00 - 12:15
Click to view confirmed speakers
Chair:
Chiara Bonini, MD, San Raffaele Scientific Institute, Italy
Speakers:
Saar Gill, MD, PhD , University of Pennsylvania, United States

Oral Abstract Presentations:

Sarah Tettamanti

Clinica Pediatrica, Università Milano Bicocca, Osp. San Gerardo/Fondazione MBBM, Italy
Balance of anti-CD123 Chimeric Antigen Receptor (CAR) binding affinity and density for the targeting of Acute Myeloid Leukemia

Annu Luostarinen
Finnish Red Cross Blood Service, Finland
Low IL-2 concentration favors generation of early memory T cells over terminal effectors during CAR T-cell expansion

Josephine Dietrich
Cellex Patient Treatment GmbH, Germany
Targeting leukemia using an inducible universal chimeric antigen receptor (UniCAR) T cell technology

Non-Malignant Diseases Immunotherapy Plenary Breakout Session 1 - MSC in Autoimmune Disease
Non-Malignant Diseases Immunotherapy Plenary Breakout Session 1 - MSC in Autoimmune Disease
11:00 - 12:15
Chair:
Fernando Figueroa, MD, University of Los Andes, Chile
Speakers:
Fernando Figueroa, MD, University of Los Andes, Chile
Farida Djouad, PhD, French Institute of Health and Medical Research, France

Oral Abstract Presentations:

Hala Gabr

Cairo University, Egypt
Autologous Mesenchymal Stem Cell Therapy in Behcet Disease

Ana Cardesa Gil
Andalusian Initiative for Advanced Therapies, Spain
A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GvHD with allogenic mesenchymal stem cells (MSC) from adipose tissue

Lunch with Exhibits
Exhibit Hall
Lunch with Exhibits
12:15 - 13:45
Exhibit Hall

Plenary Session 2 - Immunotherapy of Non-Malignant Diseases
Click to view confirmed speakers
Plenary Session 2 - Immunotherapy of Non-Malignant Diseases
13:45 - 15:15
Click to view confirmed speakers
Chair:
Giovanna Lombardi, PhD, King's College London, United Kingdom
Speakers:
Aimee Payne, MD, PhD, University of Pennsylvania, United States
Megan Levings, PhD, University of British Columbia, Canada
Fernando Figueroa, MD, University of Los Andes, Chile

T-Cell Immunotherapy Plenary Breakout Session 3 - CAR T Cells
Click to view confirmed speakers
T-Cell Immunotherapy Plenary Breakout Session 3 - CAR T Cells
15:30 - 17:00
Click to view confirmed speakers
Chair:
Martin Pule, MB BCh, University College London, United Kingdom
Speakers:
John Maher, MD, PhD King's College London, United Kingdom

Oral Abstract Presentations:

Carlos Ramos

Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, United States
DIRECT COMPARISON OF IN VIVO FATE OF SECOND AND THIRD-GENERATION CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELLS IN PATIENTS WITH B CELL NON-HODGKIN LYMPHOMA (B-NHL): REVERSAL OF TOXICITY FROM TONIC SIGNALING

George Hucks
Children's Hospital of Philadelphia, United States
Humanized Chimeric Antigen Receptor (CAR)-modified T cells Targeting CD19 Induce Remissions in Children and Young Adults with Relapsed/Refractory Lymphoblastic Leukemia/Lymphoma

David Bishop
Westmead Institute for Medical Research; Westmead Hospital; The University of Sydney, Australia
DIFFERING CO-STIMULATORY, LINKER AND SPACER DOMAINS PRODUCE VARIATIONS IN CD4 AND CD8 CELL COMPOSITION AND CYTOTOXIC POTENTIAL IN CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR19) T CELLS GENERATED WITH THE PIGGYBAC TRANSPOSASE.

Dror Mevorach
Hadassah-Hebrew University, Israel
Apoptotic Cells Therapy for the Prevention of Cytokine Release Syndrome (CRS) in CAR T-Cell Therapy

ISCT Chief Scientific Officer Abstract Showcase
ISCT Chief Scientific Officer Abstract Showcase
15:30 - 17:00
Chair:
Daniel J. Weiss, MD, PhD, University of Vermont College of Medicine, United States

Oral Abstract Presentations:

John Rasko

Royal Prince Alfred Hospital; University of Sydney; Centenary Institute, Australia
LentiGlobin Gene Therapy for Transfusion-Dependent β-Thalassemia: Update from the Northstar HGB-204 Phase 1/2 Clinical Study

Luca Urbani
UCL Great Ormond Street Institute of Child Health, United Kingdom
Development of a bioartificial oesophagus engineered with primary mesoangioblasts, neural and epithelial cells for preclinical studies

Kenneth Kotz
Draper Laboratory, United States
SEPARATION OF LYMPHOCYTES USING ACOUSTIC MICROFLUIDICS

Anthony Criquet
CellProthera, France
CHALLENGES BETWEEN CLINICAL SITES AND CELL THERAPY FACILITIES IN THE EXCELLENT TRIAL (EXPANDED CELL ENDOCARDIAC TRANSPLANTATION), A PHASE I/IIb CLINICAL TRIAL.

Michael Watts
University College London Hospitals, United Kingdom
VALIDATION OF AN ENFORCED CHANGE IN CRYOPRESERVATION METHOD AFTER HYDROXYETHYLSTARCH (HES) WITHDRAWAL: ENGRAFTMENT KINETICS OF 1007 AUTOGRAFT PROCEDURES

Yael Gothelf
BrainStorm Cell-Therapeutics, Israel
Safety and Efficacy of transplantation of NurOwn (Autologous Mesenchymal Stromal Cells Secreting Neurotrophic Factors) in Patients with ALS: a Phase 2 Randomized Double Blind Placebo Controlled Trial

Non-Malignant Diseases Immunotherapy Plenary Breakout Session 2 - Alloantigen Specific T Reg
Click to view confirmed speakers
Non-Malignant Diseases Immunotherapy Plenary Breakout Session 2 - Alloantigen Specific T Reg
15:30 - 17:00
Click to view confirmed speakers
Chair:
Megan Levings, PhD, University of British Columbia, Canada
Aimee Payne, MD, PhD, University of Pennsylvania, United States
Speakers:
Giovanna Lombardi, PhD, King's College London, United Kingdom

Oral Abstract Presentations:

Anke Fuchs (Theil)

Technische Universität Dresden, Medical Faculty; University Hospital Carl Gustav Carus, Germany
Regulatory T cell kinetics following adoptive transfer of expanded allogeneic regulatory T cells into patients with chronic graft-versus host disease

Krishna Komanduri
University of Miami, United States
Marked in vivo Donor Treg expansion via targeting of the IL-2/CD25 and TL1A/TNFRSF25 pathways ameliorates GVHD and preserves GVL

Halvard Boenig
Johann-Wolfgang-Goethe University, Frankfurt, Germany
Add back of selectively depleted alloreactive T-cells retaining the full immune repertoire of mature T-cells improves event-free survival (GRFS) and overall survival in a T-cell depleted haploidentical HSCT

Corporate Symposium - Terumo BCT
Corporate Symposium - Terumo BCT
17:30 - 19:30

Inner Column
Inner Column
Advanced Practice Professionals Track Session 1
Click to view confirmed speakers
Advanced Practice Professionals Track Session 1
07:30 - 08:30
Click to view confirmed speakers
Speakers:
Maria Gilleece, MD, FRCP, FRCPath, Leeds Teaching Hospitals Trust, United Kingdom
Saar Gill, MD, PhD, University of Pennyslvania, United States

Corporate Breakfast Tutorial - Available
Contact Brian Poole (brian@celltherapysociety.org) for more info.
Corporate Breakfast Tutorial - Available
07:30 - 08:30
Contact Brian Poole (brian@celltherapysociety.org) for more info.

Corporate Breakfast Tutorial - Available
Contact Brian Poole (brian@celltherapysociety.org) for more information.
Corporate Breakfast Tutorial - Available
07:30 - 08:30
Contact Brian Poole (brian@celltherapysociety.org) for more information.

Corporate Product Theatre - Available
Contact Brian Poole (brian@celltherapysociety.org) for more info.
Corporate Product Theatre - Available

Regulatory Track Session 1 - Global Accelerated Access Landscape - North America
Click to view confirmed speakers
Regulatory Track Session 1 - Global Accelerated Access Landscape - North America
11:00 - 12:15
Click to view confirmed speakers
Speakers:
Sowmya Viswanathan, PhD, University Health Network, Canada

Strategies for Commercialization Track Session 1 - Successful Industrialization via coordinated Reimbursement and COGs
Click to view confirmed speakers
Strategies for Commercialization Track Session 1 - Successful Industrialization via coordinated Reimbursement and COGs
11:00 - 12:15
Click to view confirmed speakers
Chair:
Dawn Driscoll, MBA, PhD, Isopogen Pty Ltd, Australia
Speakers:
Geoffrey MacKay, AVROBIO Inc, United States
Karen Hodgkin, MSc, Cell Medica Inc, United Kingdom
Eric Faulkner, MPH, Evidera, United States

Quality and Operations Track Session 1 - Risk Management
Click to view confirmed speakers
Quality and Operations Track Session 1 - Risk Management
11:00 - 12:15
Click to view confirmed speakers
Chair:
Vicki Antonenas, MSc , Westmead Hospital, Australia
Speakers:
Craig Wright, MSc, Royal Prince Alfred Hospital, Australia
Karen Burks, BSc, NHS Blood & Transplant, United Kingdom,
Olive Sturtevant, MT (ASCP), MHP, Dana Farber Cancer Institute, United States

Corporate Tutorial - Thermo Fisher Scientific
Plenary Hall
Corporate Tutorial - Thermo Fisher Scientific
12:30 - 13:30
Plenary Hall

Corporate Product Theatre - Available
Contact Brian Poole (brian@celltherapysociety.org) for more information.
Corporate Product Theatre - Available

Corporate Product Theatre - Available
Contact Brian Poole (brian@celltherapysociety.org) for more information.
Corporate Product Theatre - Available

Regulatory Track Session 2 - Global Accelerated Access Landscape - Europe, Asia and Australia
Regulatory Track Session 2 - Global Accelerated Access Landscape - Europe, Asia and Australia
15:30 - 17:00

Strategies for Commercialization Track Session 2 - Industrializing the Vein to Vein Supply Chain
Click to view confirmed speakers
Strategies for Commercialization Track Session 2 - Industrializing the Vein to Vein Supply Chain
15:30 - 17:00
Click to view confirmed speakers
Chair:
Brian Newsom, MBA, Thermo Fisher Scientific, United States
Speakers:
Vin Singh, MS, MBA, Thermo Fisher Scientific, United States
Chris Creasey, PhD, Asymptote Ltd, United Kingdom
Peter Olagunju, MBA, bluebird bio, United States

Quality and Operations Track Session 2 - Quality Control Testing - Standardization
Click to view confirmed speakers.
Quality and Operations Track Session 2 - Quality Control Testing - Standardization
15:30 - 17:00
Click to view confirmed speakers.
Chair:
Diane Kadidlo, MT(ASCP), SBB, University of Minnesota, United States
Speakers:
Saskia Ihle, PhD, Lonza Biologics, Germany
Reginald Clayton, PhD, BioReliance, United Kingdom

Poster Session 1
Poster Session 1
17:00 - 18:30

Advanced Practice Professionals Track Session 2
Advanced Practice Professionals Track Session 2
17:00 - 18:30

Inner Column
Session Type
Hot Topics
Plenary Sessions
Plenary Breakout Sessions
Early Stage Professionals Sessions
Quality and Operations Track
Corporate
07:00
07:30
08:00
08:30
09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
17:30
18:00
18:30
19:00
19:30
20:00
20:30
21:00
21:30
22:00
22:30
23:00
23:30
00:00
Hot Topic Roundtable Session 3 - Human Platelet Lysate
Click to view confirmed speakers
Hot Topic Roundtable Session 3 - Human Platelet Lysate
07:30 - 08:30
Click to view confirmed speakers
Chair:
Karen Bieback, PhD, Institute of Transfusion Medicine and Immunology , Germany
William Milligan, BSc, Steminent Biotherapeutics Inc., Canada
Speakers:
Katharina Schallmoser, MD, Paracelsus Medical University of Salzburg, Austria
Elena Jones, PhD, University of Leeds, United Kingdom
Bill Mirsch, MBA, Mill Creek Life Sciences, United States

Hot Topic Roundtable Session 4 - Biotech Financing in 2017: Challenges and Opportunities in Raising Funds
Click to view confirmed speakers
Hot Topic Roundtable Session 4 - Biotech Financing in 2017: Challenges and Opportunities in Raising Funds
07:30 - 08:30
Click to view confirmed speakers
Chair:
Miguel Forte, MD, PhD, Belgium
Speakers:
Edward Hodgkin, PhD, Syncona Partners, United Kingdom
Patrick Rivers, BS, Aquilo Capital, United States
Alex Pasteur, PhD, F-Prime, United Kingdom

Plenary Session 3 - Cancer Immunotherapy
Click to view confirmed speakers
Plenary Session 3 - Cancer Immunotherapy
08:45 - 10:15
Click to view confirmed speakers
Chair:
Katy Rezvani, MD, PhD, MD Anderson Cancer Center, United States
Speakers:
Malcolm Brenner, MChB, PhD , Baylor College of Medicine, United States
Stephan Mielke, MD, PhD, University of Wuerzburg, Germany
John Barrett, MD, National Institute of Health , United States

The translation of major advances in the understanding of cancer immune surveillance into clinical practice has been challenged by the inherent complexities of the immune system, intense regulatory requirements and a commercial reluctance by the pharmaceutical industry to invest in this modality of therapy. More recently, however, immunotherapy has made great strides against many otherwise incurable cancers both as a bridge to transplant or as a stand alone therapeutic approach. This session will highlight the methodologies used to generate various types of T cells for adoptive immunotherapy of malignant diseases, the clinical utility of the CAR T-cell approach and how to move beyond CD19 as a target and the use of alloimmunotherapy as a platform to improve the outcome of cancer.

Coffee Break with Exhibits
Coffee Break with Exhibits

Coffee Break with Exhibits
Coffee Break with Exhibits

Cancer Immunotherapy Plenary Breakout Session 1
Click to view confirmed presenters
Cancer Immunotherapy Plenary Breakout Session 1
10:45 - 12:15
Click to view confirmed presenters
Chair:
Malcolm Brenner, MChB, PhD , Baylor College of Medicine, United States

Oral Abstract Presentations:

Premal Lulla

Baylor College of Medicine; Center for Cell and Gene Therapy, United States
Administration of T cells Targeting Tumor Associated Antigens to Patients with Myeloma

Mitchell Cairo
New York Medical College, United States
Enhancement of Anti-Tumor Activity of Expanded Natural Killer Cells against GD2+ Osteosarcoma (OS) in Combination with Romidepsin (HDAC inhibitor), ALT-803 (IL-15 Superagonist) and Dinutuximab

Heba Samaha
Baylor College of Medicine; Texas Childrens Hospital; Children's Cancer Hospital Egypt, United States
A cellular platform enables targeted brain delivery of T cells

Sylvie Shen
Sydney Children's Hospital; University of New South Wales; Children's Cancer Institute for Medical Research, Australia
MODULATION OF ANTI-TUMOUR ACTIVITY OF EX VIVO EXPANDED NK CELLS AGAINST NEUROBLASTOMA VIA HDACi AND PD1/PD-L1 BLOCKADE

Steven Highfill
National Institutes of Health, United States
CD4 AND CD8 T-CELL POSITIVE SELECTION INCREASES THE ROBUSTNESS OF THE CD22 CAR T-CELL MANUFACTURING PROCESS

Cancer Immunotherapy Plenary Breakout Session 2
Click to view confirmed presenters
Cancer Immunotherapy Plenary Breakout Session 2
10:45 - 12:15
Click to view confirmed presenters
Chair:
John Barrett, MD, National Institute of Health , United States

Oral Abstract Presentations:

Rachel Burga

Institute for Biomedical Sciences; Sheikh Zayed Institute for Pediatric Surgical Innovation; Program for Cell Enhancement and Technologies for Innovation, United States
Lymphocyte-nanoparticle biohybrids as a combined nanoimmunotherapy for cancer

Anne Merete Tryggestad
Oslo University Hospital, Norway
Results from a first in man Phase I/II adjuvant Dendritic Cell Vaccine study in high risk prostate cancer patients following radical surgery

Boris Calmels
Institut Paoli-Calmettes, France
FEASIBILITY AND SAFETY OF ALLOGENEIC EX VIVO ACTIVATED-NK CELL INFUSION AFTER MATCHED RELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION: PRELIMINARY RESULTS OF A PROSPECTIVE PHASE I TRIAL

Iris Bigalke
Oslo University Hospital, Norway
WT1 and PRAME mRNA transfected TLR 7/8-polarized fast DC lead to specific immune responses in AML patients and have an impact on progression free survival

Kirsten Williams
Children's National Medical Center, United States
Complete remissions post Infusion of Multiple Tumor Antigen specific T cells for the Treatment of High Risk Leukemia and Lymphoma Patients after HCT

Lunch with Exhibits
Lunch with Exhibits
12:15 - 13:45

Lunch with Exhibits
Lunch with Exhibits
12:15 - 13:45

Plenary Session 4 - Industrialization with the Patient in Mind
Click to view confirmed speakers
Plenary Session 4 - Industrialization with the Patient in Mind
13:45 - 15:15
Click to view confirmed speakers
Chair:
Simon Ellison, MBA, Fisher BioServices UK, United Kingdom
Speakers:
Olav Hellebø, MBA, ReNeuron, United Kingdom
Marc Turner, MB, ChB, PhD, MBA, Scottish National Blood Transfusion Service, Scotland
Kurt Gunter, MD , Cell Medica Inc, United States
Sven Kili, MB, ChB, MRCS , GSK, United Kingdom

Cell and gene companies have moved through the research phase and evolved past development into viable, market ready organisations. This has been, and continues to be, a rocky road. However the evidence shows that success is reliant on creating a therapy that can treat patients beyond a clinical trial. This session will draw on learning experiences from other industries, combine them with examples from the cell and gene therapy industry to highlight the criticality of maintaining a patient focus throughout therapy development.

Cancer Immunotherapy Plenary Breakout Session 3
Click to view confirmed presenters
Cancer Immunotherapy Plenary Breakout Session 3
15:30 - 17:00
Click to view confirmed presenters
Chair:
Stephan Mielke, MD, PhD, University of Wuerzburg, Germany

Oral Abstract Presentations:

Shabnum Patel

The George Washington University; Children's National Health System, United States
HIV SPECIFIC T CELLS EXPRESSING AN X5–GPI ARTIFICIAL RECEPTOR CAN SUPPRESS HIV REPLICATION IN VITRO — IMPLICATIONS FOR A CURE STRATEGY FOR HIV+ INDIVIDUALS WITH HEMATOLOGIC MALIGNANCIES

Minoo Battiwalla
NHLBI, NIH, United States
SELECTIVE DEPLETION OF ALLOREACTIVE DONOR T CELLS WITH ADENOSINE – CLINICAL SCALE UP FOR ALLOGENEIC STEM CELL TRANSPLANTATION

Kyriakos Koukoulias
George Papanicolaou Hospital; Aristotle University, Greece
NON-TRANSPLANTABLE CORD BLOOD UNITS AS A NEW SOURCE FOR ADOPTIVE IMMUNOTHERAPY OF LEUKEMIA AND A PARADIGM OF CIRCULAR ECONOMY IN MEDICINE

Britta Eiz-Vesper
Hannover Medical School; Hannover Medical School, Germany
Modulation of heme oxygenase-1 activity to enhance WT1-specific T-cell responses for immunotherapeutic approaches

Chiara F Magnani
University of Milano-Bicocca, San Gerardo Hospital/Fondazione MBBM, Italy
PRECLINICAL EVALUATION OF DONOR-DERIVED SLEEPING BEAUTY MODIFIED CD19CAR+ LYMPHOCYTES FOR THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA

Industrial Translation Breakout Session - Industrializing: Case Studies
Click to view confirmed speakers
Industrial Translation Breakout Session - Industrializing: Case Studies
15:30 - 17:00
Click to view confirmed speakers
Chair:
Kurt Gunter, MD , Cell Medica Inc, United States
Speakers:
Patrick Rivers, BS, Aquilo Capital, United States
Eleuterio Lombardo, PhD, TiGenix SAU, Spain
Suzanne Farid, PhD, University College London, United Kingdom

MSC Oral Abstract Presentations Session 1
Click to view confirmed presenters
MSC Oral Abstract Presentations Session 1
15:30 - 17:00
Click to view confirmed presenters
Chair:
Jacques Galipeau, MD FRCP(C), University of Wisconsin in Madison, United States
Donald G. Phinney, PhD, The Scripps Research Institute, United States

Oral Abstract Presentations:

Francisco Espinoza

Universidad de los Andes, Chile
Allogeneic Mesenchymal Stromal Cell (MSC) therapy for knee osteoarthritis (OA): a phase I/II randomized controlled trial

Lipi Singh
Advancells, India
Long Term Safety and Efficacy of Autologous Stem Cell Transplantation for the treatment of Type 2 Diabetes Mellitus

Hala Gabr
Cairo University, Egypt
Comparison Between Mesenchymal Stem Cells, Stem Cell Conditioned Media, and Mesenchymal Stem Cell Derived Microsvesicles in Regeneration in Murine Model of Acute Renal Injury

Veena Krishnappa
Scripps Florida, United States
Interruption of FGFR2 Signaling Licenses the Immuno-modulatory Activity of Human MSCs by Suppressing TWIST1 Expression.

Takeo Mukai
The Institute of Medical Science, The University of Tokyo, Japan
Neurotropism and Neuroprotective effect in Umbilical cord derived-Mesenchymal Stromal Cells

Poster Session 2
Poster Session 2
17:00 - 18:30

ISCT 2017 Gala
ISCT 2017 Gala
19:00 - 00:00

Advanced Practice Professionals Track Session 3
Click to view confirmed speakers
Advanced Practice Professionals Track Session 3
07:30 - 08:30
Click to view confirmed speakers
Speakers:
Valkal Bhatt, PharmD, BCOP, Memorial Sloan Kettering Cancer Center, United States
Alex Ganetsky, PharmD, Hospital of the University of Pennsylvania, United States

Corporate Breakfast Tutorial - Irvine Scientific
Corporate Breakfast Tutorial - Irvine Scientific
07:30 - 08:30

Corporate Breakfast Tutorial - Available
Contact Brian Poole (brian@celltherapysociety.org) for more information.
Corporate Breakfast Tutorial - Available
07:30 - 08:30
Contact Brian Poole (brian@celltherapysociety.org) for more information.

Corporate Product Theatre - Miltenyi Biotec
Corporate Product Theatre - Miltenyi Biotec

Strategies for Commercialization Track Session 3 - Industrializing the CGT Business Model
Click to view confirmed speakers
Strategies for Commercialization Track Session 3 - Industrializing the CGT Business Model
10:45 - 12:15
Click to view confirmed speakers
Chair:
William Milligan, BSc, Steminent Biotherapeutics Inc., Canada
Speakers:
Matthew Durdy, MBA, Cell and Gene Therapy Catapult, United Kingdom
Dalia Mahmoud, PhD, Celgene, United States
Christopher Vann, BSc, Autolus Ltd, United Kingdom

Quality and Operations Track Session 3 - Allogeneic Cell Therapy: From HSC Transplants to Targeted T cell Therapy
Click to view confirmed speakers
Quality and Operations Track Session 3 - Allogeneic Cell Therapy: From HSC Transplants to Targeted T cell Therapy
10:45 - 12:15
Click to view confirmed speakers
Chair:
Shirley Bartido, PhD, MBA, Cellectis Inc., United States
Speakers:
Stephan Reynier, MSc, Cellectis SA, France
Ekaterina Doubrovina, MD, PhD, Memorial Sloan Kettering Cancer Center, United States
Paul Veys, MBBS, FRCP, FRCPath, FRCPCH, Great Ormond Street Hospital for Children, United Kingdom

ISCT Presidential Task Force Session
ISCT Presidential Task Force Session
10:45 - 12:15

Corporate Tutorial - BD Biosciences
Corporate Tutorial - BD Biosciences
12:30 - 13:30

Corporate Product Theatre - Available
Contact Brian Poole (brian@celltherapysociety.org) for more information.
Corporate Product Theatre - Available

Corporate Product Theatre - Available
Contact Brian Poole (brian@celltherapysociety.org) for more information.
Corporate Product Theatre - Available

Strategies for Commercialization Track Session 4 - Industrializing the Hospital of the Future
Strategies for Commercialization Track Session 4 - Industrializing the Hospital of the Future
15:30 - 17:00
Chair:
Gerhard Bauer, University of California Davis, United States
Speakers:
Miguel Forte, MD, PhD, Belgium
Shelly Heimfeld, PhD, Fred Hutchinson Cancer Research Center, United States
Ian Campbell, Innovate UK, United Kingdom

Quality and Operations Track Session 4 - Cell Characterization and Potency
Click to view confirmed speakers.
Quality and Operations Track Session 4 - Cell Characterization and Potency
15:30 - 17:00
Click to view confirmed speakers.
Speakers:
Rosa Gonzalo, MSc, PhD,University Hospital Puerta de Hierro Majadahonda, Spain
Jorge Burns, PhD, University Hospital of Modena and Reggio Emilia, Italy
Aisha Khan, ABD, MSc, MBA, University of Miami, United States
Giuseppe Astori, PhD, San Bortolo Hospital, Italy

Early Stage Professionals (ESP) Session 1 - Advanced Strategic Innovations for Cell and Gene Therapies
Click to view confirmed speakers
Early Stage Professionals (ESP) Session 1 - Advanced Strategic Innovations for Cell and Gene Therapies
15:30 - 17:00
Click to view confirmed speakers
Chair:
Emily Culme-Seymour, PhD, GSK, United Kingdom
Patrick Hanley, PhD, Children's National Medical Center, United States
Speakers:
Ben Weil, MRes, EngD, University College London, United Kingdom
Avery Posey, PhD, University of Pennsylvania, United States
Thorsten Friedel, PhD, GSK, United Kingdom

Corporate Product Theatre - Available
Contact Brian Poole (brian@celltherapysociety.org) for more information.
Corporate Product Theatre - Available

Corporate Product Theatre - Available
Contact Brian Poole (brian@celltherapysociety.org) for more information.
Corporate Product Theatre - Available

Corporate Product Theatre - Available
Contact Brian Poole (brian@celltherapysociety.org) for more information.
Corporate Product Theatre - Available

Session Type
Hot Topics
Plenary Sessions
Plenary Breakout Sessions
Strategies for Commericalization Track
Quality and Operations Track
Corporate
07:00
07:30
08:00
08:30
09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
Hot Topic Roundtable Session 5 - Novel Gene Editing Techniques
Click to view confirmed speakers
Hot Topic Roundtable Session 5 - Novel Gene Editing Techniques
07:30 - 08:30
Click to view confirmed speakers
Chair:
John Rasko, MBBS, PhD, FRCPA, FRCAP, Royal Prince Alfred Hospital, Australia
Speakers:
Madhusudan V. Peshwa, PhD, MaxCyte Inc., United States
Cliona Rooney, PhD, Baylor College of Medicine, United States

Hot Topic Roundtable Session 6 - Overcoming Analytical Challenges for Characterization of Advanced Therapies
Hot Topic Roundtable Session 6 - Overcoming Analytical Challenges for Characterization of Advanced Therapies
07:30 - 08:30
Chair:
Damian Marshall, PhD, Cell and Gene Therapy Catapult, United Kingdom

Plenary Session 5 - Editing of the Species - from Genes to Organelles to Organs
Click to view confirmed speakers
Plenary Session 5 - Editing of the Species - from Genes to Organelles to Organs
08:45 - 10:15
Click to view confirmed speakers
Chair:
John Rasko, MBBS, PhD, FRCPA, FRCAP, Royal Prince Alfred Hospital, Australia
Speakers:
Douglas Turnbull, MBBS, PhD, Newcastle University, United Kingdom
Mitochondrial donation to prevent mitochondrial DNA disease
Adrian Thrasher, MBBS, PhD, University College London, United Kingdom
Gene therapy in severe immunodeficiency
Pablo Ross, PhD, UC Davis, United States
Next-Gen X – Xenogeneic generation of human organs

Increasingly, the cells, tissues and organs being deployed as advanced therapeutic products are being engineered prior to delivery to generate or enhance therapeutic efficacy. This session, which is designed to complement and expand upon the highly successful ‘Evolution of Species’ session at the 2016 Singapore Annual Meeting, will highlight key examples of this kind of cutting-edge biological engineering. Attendees will not only gain an understanding of what is happening in clinics right now, but will also glimpse the future as they are led on a fascinating journey - from genes, through organelles and finally to whole organs - with talks from the leaders in the field.

To read Individual Presentation Descriptions, visit the Plenary Session Spotlight Page: http://isct2017.com/plenary-session-spotlight/

Coffee Break with Exhibits
Coffee Break with Exhibits

MSC Oral Abstract Presentations Session 2
Click to view confirmed presenters
MSC Oral Abstract Presentations Session 2
10:45 - 11:45
Click to view confirmed presenters

Oral Abstract Presentations:

Paolo Madeddu

University of Bristol, United Kingdom
Transplantation of allogeneic adventitial progenitor cells improves vascularization and reduces myocardial fibrosis in a swine model of reperfused acute myocardial infarction

Carlijn Voermans
Sanquin Research, Netherlands
Interferon-gamma Impairs Expansion and Hematopoietic Support of Bone Marrow Mesenchymal Stromal Cells

Sabine Geiger
apceth Biopharma GmbH, Germany
AMELIORATION OF LUNG FUNCTION AND PULMONARY TISSUE REGENERATION AFTER TREATMENT WITH AAT-EXPRESSING HUMAN MSCS IN A MURINE MODEL OF ELASTASE-INDUCED EMPHYSEMA

Sowmya Viswanathan
University Health Network; University Health Network; University of Toronto, Canada
Human Autologous Mesenchymal Stromal Cells for the Treatment of Mid- to Late-Stage Knee Osteoarthritis – Preliminary Results from a First-in-North America Phase I/II Study

Late Breaking Abstracts Session
Click to view confirmed presenters
Late Breaking Abstracts Session
10:45 - 11:45
Click to view confirmed presenters

Oral Abstract Presentations:

Lauralyn McIntyre

Ottawa Hospital Research Institute; University of Ottawa, Canada
Cellular Immunotherapy for Septic Shock (CISS): A Phase I trial

JHANN ARTURO
INMUGEN CORPORATION, Colombia
ARTERIAL REGENERATION AND CLINICAL IMPROVEMENT OF SECONDARY AUTOIMMUNE RAYNAUD'S SYNDROME WITH AUTOLOGOUS BONE MARROW MONONUCLEAR CELLS (aBM-MNC). EARLY RESULTS OF PHASE II CLINICAL TRIAL.

JEONG HUN KIM
Seoul National University; Seoul National University; Seoul National University Hospital, South Korea
In vivo Genome Editing using Cas9 Ribonucleoproteins for Choroidal Neovascularization in Age-related Macular Degeneration Animal Model

Deepak Bhere
Brigham and Women's Hospital; Harvard Medical School, United States
Mesenchymal Stem Cells shuttle microRNAs via extracellular vesicles and prime resistant GBM to caspase mediated apoptosis

Lunch with Exhibits
Lunch with Exhibits
11:45 - 13:15

Plenary Session 6 - Stem Cells for Tissue Repair and Engineering
Click to view confirmed speakers
Plenary Session 6 - Stem Cells for Tissue Repair and Engineering
13:15 - 14:45
Click to view confirmed speakers
Chair:
Massimiliano Gnecchi, MD, PhD, FESC, University of Pavia & IRCCS Policlinico San Matteo, Italy 
Speakers:
Massimiliano Gnecchi, MD, PhD, FESC, University of Pavia & IRCCS Policlinico San Matteo, Italy 
Lola Reid, PhD, University of North Carolina at Chapel Hill, United States 
Ivan Martin, PhD, University Hospital Basel, Switzerland

Tissue Repair and Engineering Breakout Session 1 - Vascular, Digestive and Respiratory Tissue Engineering
Click to view confirmed presenters
Tissue Repair and Engineering Breakout Session 1 - Vascular, Digestive and Respiratory Tissue Engineering
15:00 - 16:30
Click to view confirmed presenters

Oral Abstract Presentations:

Claire Crowley

UCL Great Ormond Street Institute of Child Health, United Kingdom
3D-culture of intestinal stem cells using an extracellular matrix hydrogel derived from decellularised intestinal tissue.

Maroun Khoury
Universidad de los Andes; Cells for Cells, Chile
Automated micro-fabrication of a vascular graft mimicking the structure of human coronary arteries based on layer deposition, nanofibers and dipping-spinning technologies

Hind Al belushi
Cancer Institute, United Kingdom
Evaluation of the chemical and biomechanical viscoelastic Properties of decellularised tracheal scaffolds

Toby Proctor
University College London; United Kingdom
PRODUCTION OF TISSUE ENGINEERED LARYNX AND EPITHELIUM IN A SINGLE GMP-COMPLIANT BIOREACTOR

Tissue Repair and Engineering Breakout Session 2 - Orthopedic Tissue Engineering
Click to view confirmed presenters
Tissue Repair and Engineering Breakout Session 2 - Orthopedic Tissue Engineering
15:00 - 16:30
Click to view confirmed presenters

Oral Abstract Presentations:

Juliana Martinez-Atienza

Andalusian Initiative for Advanced Therapies, Spain
Preliminary results of a multicenter randomized clinical trial evaluating the safety and feasibility of an allogeneic nanostructured artificial anterior human cornea

Shiva Akbarzadeh
Alfred Hospital; Monash University, Australia
CEA AS AN ADJUNCT TREATMENT FOR MAJOR BURNS: A PHASE I STUDY

Ana Fernández-González
Unidad de Producción Celular e Ingeniería Tisular. Complejo Hospitalario Universitario de Granada; Instituto de Investigación Biosanitaria ibs.GRANADA; Andalusian Initiative for Advanced Therapies, Spain
Clinical, histological and homeostasis evaluation of tissue bio-engineered skin substitute: in vivo mouse model

Ora Burger
Bonus BioGroup Ltd., Israel
BonoFillTM – A Novel Treatment for Maxillofacial Bone Tissue Regeneration

Patricia Galvez
Advanced Therapies Area, Pharmascience Division, Bioibérica S.A, Spain
Design of 3D Bioprinted Articular Cartilage of MSCs-Loaded for Osteochondral Injuries

Identifying and Optimizing Emerging Technologies to Evaluate Cell Therapy Safety, MoA and Efficacy, HESI-CT TRACS Session
Click to view confirmed speakers
Identifying and Optimizing Emerging Technologies to Evaluate Cell Therapy Safety, MoA and Efficacy, HESI-CT TRACS Session
15:00 - 16:30
Click to view confirmed speakers
Chair:
William Shingleton, PhD, GE Healthcare, United Kingdom
Speakers:
Brooke Helfer, PhD, Celsense, United States
Nobuhiro Umeda, PhD, Astellas Pharma Inc., Japan
Jeff Bulte, PhD, The Johns Hopkins Institute for Cell Engineering, United States
Yoji Sato, PhD, NIHS Japan, Japan

Strategies for Commercializaton Track Session 5 - Industrializing Talent Management
Click to view confirmed speakers
Strategies for Commercializaton Track Session 5 - Industrializing Talent Management
07:30 - 08:30
Click to view confirmed speakers
Chair:
Jim Faulkner, PhD, Autolus Ltd, United Kingdom
Speakers:
Jim Faulkner, PhD, Autolus Ltd, United Kingdom
Fungayi Chidothe, MBChB, MSc, Cell & Gene Therapy Catapult, United Kingdom
Nick Stephens, LLB, The RSA Group, United Kingdom

Quality and Operations Track Session 5 - Quality Program Design and Operations
Click to view confirmed speakers
Quality and Operations Track Session 5 - Quality Program Design and Operations
07:30 - 08:30
Click to view confirmed speakers
Chair:
Annette Trickett, PhD , Prince of Wales Hospital, Australia
Speakers:
Gerry McKiernan , Cell Therapies PTY, Australia
Nicole Prokopishyn, PhD , Calgary Laboratory Services, Canada
Robyn Rodwell, PhD, Queensland Cord Blood Bank At The Mater, Australia

Corporate Product Theatre - Available
Contact Brian Poole (brian@celltherapysociety.org) for more information.
Corporate Product Theatre - Available

Strategies for Commercialization Track Session 6 - Industrializing Processes
Click to view confirmed speakers
Strategies for Commercialization Track Session 6 - Industrializing Processes
10:45 - 11:45
Click to view confirmed speakers
Chair:
Ohad Karnieli, MBA, PhD, ATVIO Biotechnology, Israel
Speakers:
Ohad Karnieli, MBA, PhD, ATVIO Biotechnology, Israel
Sarah Callens, BSc, Cell and Gene Therapy Catapult, United Kingdom
Rodney Rietze, PhD, Novartis, United States

Quality and Operations Track Session 6 - Upkeep and Maintenance of the Human Factor: Training, Education, and Competency
Click to view confirmed speakers
Quality and Operations Track Session 6 - Upkeep and Maintenance of the Human Factor: Training, Education, and Competency
10:45 - 11:45
Click to view confirmed speakers
Chair:
Lizette Caballero, MLS(ASCP)CM, UCSF BMT Laboratory, United States
Speakers:
Carlos Lee, BSc, Carolinas Healthcare System, United States
Jacqui Thompson, BSc, NHSBT Birmingham, United Kingdom
Rosemarie Bell, B.App.Sc Micro/Biochem MASM, QIMR Berghofer Medical Research Institute, Australia

Early Stage Professionals (ESP) Session 2 - What I Wish I Knew
Click to View Confirmed Speakers
Early Stage Professionals (ESP) Session 2 - What I Wish I Knew
10:45 - 11:45
Click to View Confirmed Speakers
Chair:
Emily Hopewell, PhD, Moffitt Cancer Center, United States
Speakers:
John Rasko, MBBS, PhD, FRCPA, FRCAP, Royal Prince Alfred Hospital, Australia

ISCT Annual General Meeting
ISCT Annual General Meeting
12:00 - 13:00

Strategies for Commercialization Track Session 7 - Ancillary Materials
Click to view confirmed speakers
Strategies for Commercialization Track Session 7 - Ancillary Materials
15:00 - 16:30
Click to view confirmed speakers
Chair:
Lynn Csontos,CQA, STEMCELL Technologies Inc., Canada
Speakers:
Lynn Csontos, CQA, STEMCELL Technologies Inc., Canada
Claudia Zylberberg, PhD, Akron Biotech, United States
Jiwen Zhang, PhD, GE Healthcare, United States
Brian Newsom, MBA, Thermo Fisher Scientific, United States

Quality and Operations Track Session 7 - CMC/CTD Submission
Quality and Operations Track Session 7 - CMC/CTD Submission
15:00 - 16:30